Gary A. Lyons


Gary Lyons has served as a director of Travere Therapeutics since October 2014 and chair of the company since May 2016. Previously, Mr. Lyons was the founding president and chief executive officer of Neurocrine Biosciences, Inc. and he remains a member of its board of directors. Prior to joining Neurocrine, Mr. Lyons held a number of senior management positions at Genentech, Inc., including vice president of business development and vice president of sales. Mr. Lyons currently serves on the board of directors of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases. Previously, Mr. Lyons served on the board of directors of Eledon Pharmaceuticals, Inc. (formerly Novus Therapeutics, Inc.), from May 2017 to June 2023, and on the board of directors of Fresh Tracks Therapeutics, Inc. (formerly known as Brickell Biotech, Inc.) from August 2019 to September 2023. Mr. Lyons is also a senior advisor for HealthCare Royalty Partners. Mr. Lyons holds a B.A. in marine biology from the University of New Hampshire and an MBA. from Northwestern University’s J.L. Kellogg Graduate School of Management.